Skip to main content
. 2019 Dec 6;39(12):BSR20191698. doi: 10.1042/BSR20191698

Table 2. Results of pooled analysis for TLR2 polymorphism and cancer susceptibility.

Comparison Subgroup n Cases Controls PH PZ HR (95% CI)
(-196 to -174del)
B vs. A Overall 18 3943 6394 <0.001 0.005* 1.468 (1.129–1.91)
BB vs. AA Overall 18 3943 6394 <0.001 0.005* 1.716 (1.178–2.5)
BA vs. AA Overall 18 3943 6394 <0.001 0.008* 1.408 (1.092–1.816)
BB+BA vs. AA Overall 18 3943 6394 <0.001 0.007* 1.449 (1.107–1.897)
BB vs. BA+ AA Overall 18 3943 6394 <0.001 0.013* 1.517 (1.092–2.107)
B vs. A Asian 11 2807 4482 <0.001 0.043* 1.169 (1.005–1.361)
BB vs. AA Asian 11 2807 4482 0.003 0.098 1.373 (0.943–2)
BA vs. AA Asian 11 2807 4482 0.039 0.054 1.168 (0.997–1.367)
BB+BA vs. AA Asian 11 2807 4482 0.008 0.033* 1.203 (1.015–1.427)
BB vs. BA+ AA Asian 11 2807 4482 0.005 0.177 1.256 (0.902–1.748)
B vs. A Caucasian 3 624 1052 <0.001 0.028* 3.291 (1.139–9.51)
BB vs. AA Caucasian 3 624 1052 0.007 0.008* 9.878 (1.83–53.322)
BA vs. AA Caucasian 3 624 1052 <0.001 0.044* 3.156 (1.034–9.634)
BB+BA vs. AA Caucasian 3 624 1052 <0.001 0.034* 3.555 (1.098–11.51)
BB vs. BA+ AA Caucasian 3 624 1052 0.029 0.006* 7.294 (1.752–30.369)
B vs. A African 4 512 860 0.653 0.159 1.163 (0.943–1.436)
BB vs. AA African 4 512 860 0.796 0.746 1.076 (0.693–1.67)
BA vs. AA African 4 512 860 0.652 0.075 1.296 (0.974–1.724)
BB+BA vs. AA African 4 512 860 0.72 0.106 1.232 (0.956–1.586)
BB vs. BA+AA African 4 512 860 0.755 0.897 1.029 (0.666–1.59)
B vs. A PB 14 2904 3782 <0.001 0.001* 1.576 (1.193–2.08)
BB vs. AA PB 14 2904 3782 <0.001 0.001* 2.274 (1.43–3.616)
BA vs. AA PB 14 2904 3782 <0.001 0.005* 1.543 (1.143–2.081)
BB+BA vs. AA PB 14 2904 3782 <0.001 0.002* 1.624 (1.186–2.223)
BB vs. BA+AA PB 14 2904 3782 0.001 0.001* 2.011 (1.317–3.07)
B vs. A HB 4 1039 2612 0.016 0.502 0.92 (0.721–1.173)
BB vs. AA HB 4 1039 2612 0.048 0.552 0.866 (0.54–1.39)
BA vs. AA HB 4 1039 2612 0.122 0.841 0.984 (0.837–1.156)
BB+BA vs. AA HB 4 1039 2612 0.038 0.716 0.942 (0.684–1.298)
BB vs. BA+AA HB 4 1039 2612 0.121 0.43 0.917 (0.739–1.138)
B vs. A Gastric cancer 6 1640 2983 <0.001 0.194 1.22 (0.904–1.647)
BB vs. AA Gastric cancer 6 1640 2983 <0.001 0.176 1.565 (0.818–2.995)
BA vs. AA Gastric cancer 6 1640 2983 0.002 0.309 1.171 (0.864–1.586)
BB+BA vs. AA Gastric cancer 6 1640 2983 <0.001 0.216 1.246 (0.879–1.764)
BB vs. BA+AA Gastric cancer 6 1640 2983 <0.001 0.223 1.401 (0.814–2.411)
B vs. A Breast cancer 3 795 1350 <0.001 0.212 2.31 (0.621–8.593)
BB vs. AA Breast cancer 3 795 1350 <0.001 0.2 4.049 (0.478–34.306)
BA vs. AA Breast cancer 3 795 1350 <0.001 0.197 2.347 (0.642–8.58)
BB+BA vs. AA Breast cancer 3 795 1350 <0.001 0.2 2.52 (0.613–10.36)
BB vs. BA+AA Breast cancer 3 795 1350 <0.001 0.233 3.176 (0.476–21.196)
B vs. A Cervical cancer 4 504 770 0.474 0.269 1.121 (0.916–1.372)
BB vs. AA Cervical cancer 4 504 770 0.453 0.782 1.061 (0.696–1.618)
BA vs. AA Cervical cancer 4 504 770 0.554 0.177 1.215 (0.916–1.613)
BB+BA vs. AA Cervical cancer 4 504 770 0.586 0.207 1.177 (0.914–1.515)
BB vs. BA+AA Cervical cancer 4 504 770 0.456 0.848 1.041 (0.692–1.566)
B vs. A Y 15 3459 5620 <0.001 0.008* 1.447 (1.103–1.897)
BB vs. AA Y 15 3459 5620 <0.001 0.004* 1.915 (1.227–2.991)
BA vs. AA Y 15 3459 5620 <0.001 0.02* 1.422 (1.057–1.915)
BB+BA vs. AA Y 15 3459 5620 <0.001 0.013* 1.494 (1.088–2.052)
BB vs. BA+AA Y 15 3459 5620 <0.001 0.009* 1.673 (1.137–2.461)
B vs. A N 3 484 774 0.709 0.14 1.168 (0.951–1.434)
BB vs. AA N 3 484 774 0.597 0.84 1.05 (0.655–1.681)
BA vs. AA N 3 484 774 0.872 0.039* 1.335 (1.015–1.757)
BB+BA vs. AA N 3 484 774 0.839 0.07 1.258 (0.981–1.613)
BB vs. BA+AA N 3 484 774 0.615 0.959 0.988 (0.62–1.575)
rs3804099
B vs. A Overall 9 1901 2618 0.001 0.723 0.967 (0.806–1.162)
BB vs. AA Overall 9 1901 2618 0.029 0.29 0.84 (0.609–1.16)
BA vs. AA Overall 9 1901 2618 0.643 0.008* 0.827 (0.717–0.952)
BB+BA vs. AA Overall 9 1901 2618 0.446 0.016* 0.85 (0.744–0.97)
BB vs. BA+AA Overall 10 3456 4574 0.001 0.946 0.991 (0.768–1.28)
B vs. A Asian 5 783 1288 0.013 0.177 0.838 (0.648–1.083)
BB vs. AA Asian 5 783 1288 0.721 0.005* 0.65 (0.482–0.877)
BA vs. AA Asian 5 783 1288 0.892 0.001* 0.69 (0.55–0.867)
BB+BA vs. AA Asian 5 783 1288 0.994 <0.001 0.684 (0.555–0.843)
BB vs. BA+AA Asian 5 783 1288 0.005 0.559 0.869 (0.542–1.393)
B vs. A Caucasian 4 1118 1330 0.025 0.3 1.147 (0.885–1.486)
BB vs. AA Caucasian 4 1118 1330 0.024 0.455 1.283 (0.667–2.47)
BA vs. AA Caucasian 4 1118 1330 0.819 0.425 0.929 (0.774–1.114)
BB+BA vs. AA Caucasian 4 1118 1330 0.87 0.866 0.985 (0.829–1.171)
BB vs. BA+AA Caucasian 5 2673 3286 0.01 0.647 1.082 (0.771–1.518)
B vs. A Breast cancer 2 214 235 0.647 0.364 0.885 (0.68–1.152)
BB vs. AA Breast cancer 2 214 235 0.611 0.399 0.796 (0.47–1.351)
BA vs. AA Breast cancer 2 214 235 0.887 0.302 0.792 (0.509–1.233)
BB+BA vs. AA Breast cancer 2 214 235 0.765 0.276 0.793 (0.523–1.203)
BB vs. BA+AA Breast cancer 2 214 235 0.621 0.713 0.921 (0.592–1.432)
B vs. A Gastric Cancer 2 336 808 0.831 0.002* 0.728 (0.594–0.893)
BB vs. AA Gastric Cancer 2 336 808 0.75 0.026* 0.605 (0.389–0.942)
BA vs. AA Gastric Cancer 2 336 808 0.926 0.018* 0.706 (0.529–0.942)
BB+BA vs. AA Gastric Cancer 2 336 808 0.956 0.004* 0.681 (0.524–0.886)
BB vs. BA+AA Gastric Cancer 2 336 808 0.928 0.083 0.683 (0.444–1.051)
BB vs. BA+ AA Colon Cancer 2 1666 2058 0.243 0.034* 0.841 (0.716–0.987)
B vs. A PB 5 1172 1400 0.004 0.985 0.997 (0.759–1.311)
BB vs. AA PB 5 1172 1400 0.01 0.762 0.912 (0.502–1.658)
BA vs. AA PB 5 1172 1400 0.764 0.252 0.901 (0.754–1.077)
BB+BA vs. AA PB 5 1172 1400 0.468 0.385 0.928 (0.785–1.098)
BB vs. BA+AA PB 6 2727 3356 0.021 0.549 0.915 (0.683–1.225)
B vs. A HB 4 729 1218 0.007 0.658 0.934 (0.691–1.263)
BB vs. AA HB 4 729 1218 0.29 0.155 0.794 (0.577–1.091)
BA vs. AA HB 4 729 1218 0.624 0.005* 0.713 (0.564–0.902)
BB+BA vs. AA HB 4 729 1218 0.679 0.005* 0.734 (0.591–0.912)
BB vs. BA+AA HB 4 729 1218 0.012 0.782 1.073 (0.65–1.772)
B vs. A Y 5 1327 1792 0.13 0.036* 0.895 (0.807–0.993)
BB vs. AA Y 5 1327 1792 0.233 0.087 0.828 (0.668–1.028)
BA vs. AA Y 5 1327 1792 0.484 0.058 0.856 (0.729–1.005)
BB+BA vs. AA Y 5 1327 1792 0.258 0.028* 0.844 (0.725–0.982)
BB vs. BA+ AA Y 5 1327 1792 0.437 0.265 0.898 (0.742–1.086)
B vs. A N 4 574 826 0.004 0.37 1.179 (0.823–1.688)
BB vs. AA N 4 574 826 0.008 0.596 1.262 (0.534–2.98)
BA vs. AA N 4 574 826 0.628 0.042* 0.73 (0.54–0.988)
BB+BA vs. AA N 4 574 826 0.469 0.315 0.87 (0.663–1.142)
BB vs. BA+AA N 4 574 826 0.002 0.242 1.564 (0.739–3.308)
rs3804100
B vs. A Overall 8 2842 3081 0.422 0.254 1.076 (0.949–1.219)
BB vs. AA Overall 8 2842 3081 0.682 0.412 0.823 (0.516–1.311)
BA vs. AA Overall 8 2842 3081 0.487 0.603 1.041 (0.896–1.209)
BB+BA vs. AA Overall 8 2842 3081 0.758 0.641 1.035 (0.894–1.199)
BB vs. BA+AA Overall 8 2842 3081 0.243 0.061 1.343 (0.987–1.827)
B vs. A Asian 5 622 1005 0.152 0.71 1.037 (0.856–1.257)
BB vs. AA Asian 5 622 1005 0.66 0.153 0.655 (0.366–1.17)
BA vs. AA Asian 5 622 1005 0.276 0.543 0.917 (0.692–1.213)
BB+BA vs. AA Asian 5 622 1005 0.688 0.391 0.888 (0.677–1.165)
BB vs. BA+AA Asian 5 622 1005 0.105 0.079 1.346 (0.966–1.875)
B vs. A Caucasian 3 2220 2076 0.937 0.237 1.105 (0.937–1.304)
BB vs. AA Caucasian 3 2220 2076 0.618 0.494 1.337 (0.582–3.075)
BA vs. AA Caucasian 3 2220 2076 0.87 0.317 1.095 (0.917–1.308)
BB+BA vs. AA Caucasian 3 2220 2076 0.908 0.268 1.104 (0.927–1.315)
BB vs. BA+AA Caucasian 3 2220 2076 0.612 0.51 1.323 (0.576–3.039)
B vs. A PB 4 2269 2142 0.365 0.555 1.049 (0.896–1.228)
BB vs. AA PB 4 2269 2142 0.471 0.91 0.959 (0.465–1.977)
BA vs. AA PB 4 2269 2142 0.402 0.495 1.061 (0.894–1.26)
BB+BA vs. AA PB 4 2269 2142 0.384 0.514 1.057 (0.894–1.251)
BB vs. BA+ AA PB 4 2269 2142 0.479 0.911 0.96 (0.466–1.978)
B vs. A HB 4 573 939 0.308 0.266 1.124 (0.915–1.381)
BB vs. AA HB 4 573 939 0.512 0.336 0.74 (0.4–1.368)
BA vs. AA HB 4 573 939 0.346 0.872 0.975 (0.715–1.329)
BB+BA vs. AA HB 4 573 939 0.83 0.829 0.967 (0.715–1.308)
BB vs. BA+AA HB 4 573 939 0.146 0.033* 1.449 (1.031–2.036)
B vs. A Breast cancer 2 213 241 0.429 0.886 0.968 (0.617–1.517)
BA vs. AA Breast cancer 2 213 241 0.663 0.662 1.118 (0.679–1.839)
BB+BA vs. AA Breast cancer 2 213 241 0.533 0.867 1.042 (0.641–1.695)
B vs. A Gastric cancer 2 173 524 0.493 0.598 0.918 (0.669–1.261)
BB vs. AA Gastric cancer 2 173 524 0.259 0.168 0.481 (0.17–1.362)
BA vs. AA Gastric cancer 2 173 524 0.88 0.531 1.129 (0.772–1.652)
BB+BA vs. AA Gastric cancer 2 173 524 0.675 0.927 1.018 (0.703–1.473)
BB vs. BA+AA Gastric cancer 2 173 524 0.27 0.142 0.463 (0.165–1.295)
B vs. A Y 6 2543 2537 0.666 0.546 1.045 (0.905–1.207)
BB vs. AA Y 6 2543 2537 0.706 0.824 0.935 (0.516–1.695)
BA vs. AA Y 6 2543 2537 0.683 0.436 1.065 (0.909–1.248)
BB+BA vs. AA Y 6 2543 2537 0.688 0.467 1.059 (0.907–1.237)
BB vs. BA+AA Y 6 2543 2537 0.693 0.771 0.916 (0.508–1.653)
B vs. A N 2 299 544 0.075 0.741 1.091 (0.652–1.824)
BB vs. AA N 2 299 544 0.188 0.308 0.674 (0.316–1.439)
BA vs. AA N 2 299 544 0.108 0.507 0.855 (0.537–1.36)
BB+BA vs. AA N 2 299 544 0.563 0.499 0.855 (0.543–1.346)
BB vs. BA+AA N 2 299 544 0.073 0.789 0.716 (0.062–8.24)
rs4696480
B vs. A Overall 4 492 500 0.323 0.03* 1.216 (1.019–1.452)
BB vs. AA Overall 4 492 500 0.344 0.032* 1.463 (1.034–2.069)
BA vs. AA Overall 4 492 500 0.059 0.167 1.407 (0.867–2.281)
BB+BA vs. AA Overall 4 492 500 0.076 0.115 1.415 (0.919–2.179)
BB vs. BA+AA Overall 4 492 500 0.836 0.296 1.169 (0.872–1.568)
B vs. A Asian 2 232 230 0.628 0.772 1.039 (0.801–1.348)
BB vs. AA Asian 2 232 230 0.563 0.692 1.106 (0.671–1.824)
BA vs. AA Asian 2 232 230 0.711 0.77 0.939 (0.616–1.433)
BB+BA vs. AA Asian 2 232 230 0.981 0.968 0.992 (0.672–1.465)
BB vs. BA+AA Asian 2 232 230 0.382 0.596 1.125 (0.728–1.738)
B vs. A Caucasian 2 260 270 0.424 0.007* 1.393 (1.094–1.775)
BB vs. AA Caucasian 2 260 270 0.406 0.009* 1.903 (1.171–3.091)
BA vs. AA Caucasian 2 260 270 0.252 0.001* 1.984 (1.307–3.012)
BB+BA vs. AA Caucasian 2 260 270 0.261 0.001* 1.95 (1.317–2.887)
BB vs. BA+AA Caucasian 2 0.848 0.351 1.208 (0.812–1.798)
B vs. A PB 3 307 319 0.21 0.176 1.167 (0.933–1.458)
BB vs. AA PB 3 307 319 0.217 0.152 1.369 (0.891–2.105)
BA vs. AA PB 3 307 319 0.044 0.421 1.322 (0.67–2.611)
BB+BA vs. AA PB 3 307 319 0.056 0.349 1.336 (0.729–2.449)
BB vs. BA+AA PB 3 307 319 0.652 0.408 1.167 (0.809–1.681)
B vs. A Y 3 417 411 0.463 0.158 1.15 (0.947–1.396)
BB vs. AA Y 3 417 411 0.502 0.163 1.31 (0.897–1.916)
BA vs. AA Y 3 417 411 0.183 0.238 1.211 (0.881–1.665)
BB+BA vs. AA Y 3 417 411 0.227 0.158 1.239 (0.921–1.666)
BB vs. BA+AA Y 3 427 411 0.677 0.412 1.146 (0.827–1.588)
rs5743708
B vs. A Overall 2 309 572 <0.001 0.321 4.076 (0.255–65.24)
BA vs. AA Overall 2 309 572 0.022 0.338 1.697 (0.575–5.011)
BB+BA vs. AA Overall 4 2618 3487 <0.001 0.312 1.651 (1.348–2.022)
rs1898830
B vs. A Overall 3 2520 3146 0.391 0.939 1.003 (0.928–1.085)
BB vs. AA Overall 3 2520 3146 0.323 0.646 0.961 (0.809–1.14)
BA vs. AA Overall 3 2520 3146 0.056 0.806 0.971 (0.768–1.227)
BB+BA vs. AA Overall 3 2520 3146 0.075 0.813 0.975 (0.791–1.202)
BB vs. BA+AA Overall 3 2520 3146 0.998 0.77 0.977 (0.835–1.143)
B vs. A Caucasian 2 2309 2914 0.623 0.655 1.019 (0.939–1.106)
BB vs. AA Caucasian 2 2309 2914 0.779 0.972 1.003 (0.837–1.202)
BA vs. AA Caucasian 2 2309 2914 0.515 0.355 1.056 (0.941–1.187)
BB+BA vs. AA Caucasian 2 2309 2914 0.518 0.433 1.045 (0.936–1.167)
BB vs. BA+AA Caucasian 2 2309 2914 0.955 0.777 0.975 (0.822–1.158)
B vs. A PB 2 2309 2914 0.623 0.655 1.019 (0.939–1.106)
BB vs. AA PB 2 2309 2914 0.779 0.972 1.003 (0.837–1.202)
BA vs. AA PB 2 2309 2914 0.515 0.355 1.056 (0.941–1.187)
BB+BA vs. AA PB 2 2309 2914 0.518 0.433 1.045 (0.936–1.167)
BB vs. BA+AA PB 2 2309 2914 0.955 0.777 0.975 (0.822–1.158)

Abbreviations: n, polymorphisms did not conform to HWE in the control group; P-B, population based; PH, P-value of Q test for heterogeneity test; PZ, means statistically significant (P<0.05); Y, polymorphisms conformed to HWE in the control group.

* P-value less than 0.05 was considered as statistically significant.